Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8IU54
UPID:
IFNL1_HUMAN
Alternative names:
Cytokine Zcyto21; Interleukin-29
Alternative UPACC:
Q8IU54; A0AV25; Q17R34
Background:
Interferon lambda-1, known alternatively as Cytokine Zcyto21 or Interleukin-29, plays a pivotal role in the body's defense mechanisms against viral infections, particularly in epithelial tissues. It activates the JAK/STAT signaling pathway through its unique receptor, leading to the expression of antiviral genes. Its activity is highly specific to epithelial cells, attributed to the exclusive expression of its receptor IFNLR1 in these cells.
Therapeutic significance:
Understanding the role of Interferon lambda-1 could open doors to potential therapeutic strategies, especially in enhancing antiviral and immunomodulatory responses in epithelial tissues.